Welcome to our dedicated page for Seer news (Ticker: SEER), a resource for investors and traders seeking the latest updates and insights on Seer stock.
Seer, Inc., a prominent player in the life sciences sector, is revolutionizing the field of proteomics. The company is known for its development and commercialization of the Proteograph Product Suite, an integrated solution designed to unlock deep, unbiased biological information. The suite comprises consumables, automation instrumentation, and software that enable comprehensive proteomic profiling and sample analysis, providing researchers with a detailed view of the proteome.
Seer's technology is built around proprietary engineered nanoparticles, which offer unmatched depth and scale in proteomic studies. This innovative approach allows for the detection of over 6,000 proteins and more than 55,000 peptide IDs in complex samples, such as plasma. The Proteograph Product Suite is designed for ease of use, with features like minimal hands-on time and fully automated workflows, making it accessible to a wide range of research labs.
The company primarily targets academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies, offering its products for non-diagnostic and non-clinical purposes. Seer has established significant collaborations with industry leaders like Discovery Life Sciences, Bruker Scientific LLC, and Thermo Electron North America LLC, enhancing its market reach and technological capabilities.
Recently, Seer has made headlines through its partnership with Panome Bio to integrate deep, unbiased proteomics with metabolomics, aiming to accelerate research in biomarker discovery and drug development. The collaboration is expected to facilitate groundbreaking studies with robust pathway analyses, significantly advancing the understanding of biology and disease.
In another noteworthy development, Seer announced a major study published in Nature Communications, conducted in collaboration with Weill Cornell Medicine. This research showcased Seer's Proteograph workflow's potential to unveil novel proteogenomic insights, linking genetic variation with protein abundance at peptide level resolution. This study is a testament to Seer's commitment to advancing multi-omics research and enhancing precision medicine.
Seer's financial outlook remains optimistic despite macroeconomic challenges. The company continues to drive the adoption of its Proteograph Product Suite by expanding its Technology Access Center and increasing its commercial reach. As more customer data and third-party publications highlight the power of Seer's technology, the company anticipates growing adoption and impact in the scientific community.
In summary, Seer, Inc. is at the forefront of proteomics, offering transformative solutions that provide unparalleled insights into the proteome, thus paving the way for significant advancements in biological research and precision medicine.
Seer, a life sciences company, will report its Q1 2021 financial results after the market closes on May 10, 2021. The management team will host a conference call starting at 1:30 p.m. PT / 4:30 p.m. ET. Investors can access the live audio webcast on Seer’s website, with an archived replay available post-event. Seer's focus is on advancing proteomics through its Proteograph™ Product Suite, designed for deep, unbiased analysis in life sciences research.
Seer has entered a non-exclusive agreement with SCIEX to combine their technologies, enhancing proteomics workflows for diverse laboratories. This partnership integrates SCIEX's mass spectrometry with Seer's Proteograph Product Suite, facilitating unbiased and deep proteomics studies at scale. The Proteograph system, featuring engineered nanoparticles and advanced automation, aims to accelerate research by providing comprehensive protein analysis with unprecedented sensitivity and speed. Both companies anticipate future collaborations to further innovate in proteomics.
Seer, Inc. (Nasdaq: SEER) reported financial results for the year and fourth quarter ended December 31, 2020. Revenue surged to $656,000, up from $116,000 in 2019, driven by grants and collaboration studies. However, operating expenses rose sharply by 102% to $34.3 million, leading to a net loss of $32.8 million. Seer announced significant partnerships, including with the Salk Institute and SCIEX, while strengthening its balance sheet with $417.5 million in net proceeds from its IPO and follow-on offering. The company is transitioning to the second phase of its commercialization plan.
Seer, Inc. (Nasdaq: SEER) announced it will report its financial results for Q4 and full year 2020 on March 29, 2021, after market close. The company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET, available for live audio on their Investor website. Seer specializes in proteomics and is developing the Proteograph Product Suite, aimed at revolutionizing biological information analysis for life sciences research. The product suite operates efficiently and is not intended for diagnostics.
Seer, a life sciences company listed on Nasdaq under the symbol SEER, will participate in the Cowen 41st Annual Healthcare Conference on March 3, 2021. The management will engage in a fireside chat at 8:40 a.m. PT / 11:40 a.m. ET. A live webcast will be accessible on the company’s investor website, with an archived replay available post-conference. Seer focuses on enhancing scientific outcomes through its Proteograph™ Product Suite, designed for comprehensive proteomics analysis in a short time frame.
Seer, Inc. (Nasdaq: SEER) has appointed Deep Nishar and Dr. Mostafa Ronaghi to its Board of Directors, effective February 13, 2020. Nishar, a Senior Managing Partner at SoftBank, has extensive experience in tech companies such as Google and LinkedIn. Dr. Ronaghi is a former CTO of Illumina and co-founder of Grail. Their appointments aim to enhance Seer’s leadership in the proteomics field, promoting innovative approaches to biological insights and market expansion. The company's Proteograph™ Product Suite aims to provide deep, unbiased proteomics analysis, advancing scientific outcomes.
Seer, a life sciences company, announced the closing of a public offering of 3,750,000 shares of Class A common stock at $67.00 per share, generating $251.25 million before commissions. In this offering, Seer sold 1,650,000 shares while 2,100,000 shares were sold by existing stockholders. The offering was managed by J.P. Morgan, Morgan Stanley, BofA Securities, and Cowen. The SEC approved the offering on January 27, 2021. The funds raised will be used to enhance Seer's proteomics platform, including the Proteograph Product Suite.
Seer, a life sciences company, has announced a public offering of 3,750,000 shares of Class A common stock at $67.00 per share. The offering includes 1,650,000 shares from Seer and 2,100,000 from selling stockholders. There is a 30-day option for underwriters to purchase an additional 562,500 shares. The offering is expected to close around February 1, 2021. Major investment banks involved are J.P. Morgan, Morgan Stanley, BofA Securities, and Cowen. Seer will not receive proceeds from selling stockholders' shares.
Seer, Inc. announced a proposed underwritten public offering of 3,500,000 shares of Class A common stock, with 1,400,000 shares offered by the company and 2,100,000 shares by selling stockholders. The offering includes a 30-day option for underwriters to purchase an additional 525,000 shares. Proceeds will support the commercialization and development of the Proteograph Product Suite and may also fund potential acquisitions. The offering's completion is subject to market conditions, and no assurance is given regarding timing or terms.
Seer (NASDAQ: SEER) has announced a non-exclusive commercial agreement with Thermo Fisher Scientific, enabling the integration of Thermo Fisher’s Orbitrap mass spectrometry systems with Seer’s Proteograph Product Suite. This collaboration aims to enhance end-to-end proteomics workflows, helping researchers achieve unbiased, deep proteome analysis. With both companies committed to advancing proteomics in emerging fields like proteogenomics, the combined solution will be readily available, reflecting a significant step toward expanding proteomics accessibility in various scientific markets.
FAQ
What is the current stock price of Seer (SEER)?
What is the market cap of Seer (SEER)?
What is Seer, Inc. known for?
What does the Proteograph Product Suite include?
Who are Seer's primary customers?
What recent collaborations has Seer announced?
What are the benefits of Seer's proprietary engineered nanoparticles?
What was the focus of Seer's recent study published in Nature Communications?
What is Seer's strategy to drive adoption of its technology?
Is the Proteograph Product Suite intended for diagnostic use?
Where is Seer, Inc. headquartered?
What potential does Seer see in its technology?
